395 related articles for article (PubMed ID: 19706860)
1. Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction.
Nanda A; Chen MH; Braccioforte MH; Moran BJ; D'Amico AV
JAMA; 2009 Aug; 302(8):866-73. PubMed ID: 19706860
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant hormonal therapy use and the risk of death in men with prostate cancer treated with brachytherapy who have no or at least a single risk factor for coronary artery disease.
Nanda A; Chen MH; Moran BJ; Braccioforte MH; Dosoretz D; Salenius S; Katin M; Ross R; D'Amico AV
Eur Urol; 2014 Jan; 65(1):177-85. PubMed ID: 22981136
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular comorbidity and mortality in men with prostate cancer treated with brachytherapy-based radiation with or without hormonal therapy.
Nanda A; Chen MH; Moran BJ; Braccioforte MH; D'Amico AV
Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):e209-15. PubMed ID: 23332383
[TBL] [Abstract][Full Text] [Related]
4. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial.
D'Amico AV; Chen MH; Renshaw AA; Loffredo M; Kantoff PW
JAMA; 2008 Jan; 299(3):289-95. PubMed ID: 18212313
[TBL] [Abstract][Full Text] [Related]
5. Association of androgen-deprivation therapy with excess cardiac-specific mortality in men with prostate cancer.
Ziehr DR; Chen MH; Zhang D; Braccioforte MH; Moran BJ; Mahal BA; Hyatt AS; Basaria SS; Beard CJ; Beckman JA; Choueiri TK; D'Amico AV; Hoffman KE; Hu JC; Martin NE; Sweeney CJ; Trinh QD; Nguyen PL
BJU Int; 2015 Sep; 116(3):358-65. PubMed ID: 25124891
[TBL] [Abstract][Full Text] [Related]
6. Radical prostatectomy vs radiation therapy and androgen-suppression therapy in high-risk prostate cancer.
Westover K; Chen MH; Moul J; Robertson C; Polascik T; Dosoretz D; Katin M; Salenius S; D'Amico AV
BJU Int; 2012 Oct; 110(8):1116-21. PubMed ID: 22540922
[TBL] [Abstract][Full Text] [Related]
7. Duration of the anti-androgen in men undergoing 6 months of an LHRH agonist and radiation therapy for unfavorable-risk prostate cancer and the risk of death.
Sanford NN; Chen MH; Loffredo M; Renshaw A; Kantoff PW; D'Amico AV
Prostate Cancer Prostatic Dis; 2017 Mar; 20(1):79-84. PubMed ID: 27824043
[TBL] [Abstract][Full Text] [Related]
8. Mortality in men with localized prostate cancer treated with brachytherapy with or without neoadjuvant hormone therapy.
Dosoretz AM; Chen MH; Salenius SA; Ross RH; Dosoretz DE; Katin MJ; Mantz C; Nakfoor BM; D'Amico AV
Cancer; 2010 Feb; 116(4):837-42. PubMed ID: 20052734
[TBL] [Abstract][Full Text] [Related]
9. Race and mortality risk after radiation therapy in men treated with or without androgen-suppression therapy for favorable-risk prostate cancer.
Kovtun KA; Chen MH; Braccioforte MH; Moran BJ; D'Amico AV
Cancer; 2016 Dec; 122(23):3608-3614. PubMed ID: 27490845
[TBL] [Abstract][Full Text] [Related]
10. Coronary revascularization and mortality in men with congestive heart failure or prior myocardial infarction who receive androgen deprivation.
Nguyen PL; Chen MH; Goldhaber SZ; Martin NE; Beard CJ; Dosoretz DE; Katin MJ; Ross R; Salenius SA; D'Amico AV
Cancer; 2011 Jan; 117(2):406-13. PubMed ID: 21108457
[TBL] [Abstract][Full Text] [Related]
11. Influence of androgen deprivation therapy on all-cause mortality in men with high-risk prostate cancer and a history of congestive heart failure or myocardial infarction.
Nguyen PL; Chen MH; Beckman JA; Beard CJ; Martin NE; Choueiri TK; Hu JC; Hoffman KE; Dosoretz DE; Moran BJ; Salenius SA; Braccioforte MH; Kantoff PW; D'Amico AV; Ennis RD
Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):1411-6. PubMed ID: 21708431
[TBL] [Abstract][Full Text] [Related]
12. Influence of Comorbidity on the Risk of Mortality in Men With Unfavorable-Risk Prostate Cancer Undergoing High-Dose Radiation Therapy Alone.
Huynh MA; Chen MH; Wu J; Braccioforte MH; Moran BJ; D'Amico AV
Int J Radiat Oncol Biol Phys; 2016 Jul; 95(4):1158-67. PubMed ID: 27209511
[TBL] [Abstract][Full Text] [Related]
13. Androgen-suppression therapy for prostate cancer and the risk of death in men with a history of myocardial infarction or stroke.
Hayes JH; Chen MH; Moran BJ; Braccioforte MH; Dosoretz DE; Salenius S; Katin MJ; Ross R; Choueiri TK; D'Amico AV
BJU Int; 2010 Oct; 106(7):979-85. PubMed ID: 20230380
[TBL] [Abstract][Full Text] [Related]
14. Androgen deprivation therapy and the risk of death from prostate cancer among men with favorable or unfavorable intermediate-risk disease.
Keane FK; Chen MH; Zhang D; Moran BJ; Braccioforte MH; D'Amico AV
Cancer; 2015 Aug; 121(16):2713-9. PubMed ID: 25925789
[TBL] [Abstract][Full Text] [Related]
15. Identification of comorbidities that place men at highest risk of death from androgen deprivation therapy before brachytherapy for prostate cancer.
Parekh A; Chen MH; D'Amico AV; Dosoretz DE; Ross R; Salenius S; Graham PL; Beckman JA; Beard CJ; Choueiri TK; Ennis RD; Hoffman KE; Hu JC; Ma J; Martin NE; Nguyen PL
Brachytherapy; 2013; 12(5):415-21. PubMed ID: 23651926
[TBL] [Abstract][Full Text] [Related]
16. Prostate cancer-specific mortality and the extent of therapy in healthy elderly men with high-risk prostate cancer.
Hoffman KE; Chen MH; Moran BJ; Braccioforte MH; Dosoretz D; Salenius S; Katin MJ; Ross R; D'Amico AV
Cancer; 2010 Jun; 116(11):2590-5. PubMed ID: 20310055
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant hormone therapy for radical prostate radiotherapy: bicalutamide monotherapy vs. luteinizing hormone-releasing hormone agonist monotherapy: a single-institution matched-pair analysis.
McGivern U; Mitchell DM; McDowell C; O'Hare J; Corey G; O'Sullivan JM
Clin Genitourin Cancer; 2012 Sep; 10(3):190-5. PubMed ID: 22677511
[TBL] [Abstract][Full Text] [Related]
18. Six-month androgen suppression plus radiation therapy compared with radiation therapy alone for men with prostate cancer and a rapidly increasing pretreatment prostate-specific antigen level.
D'Amico AV; Loffredo M; Renshaw AA; Loffredo B; Chen MH
J Clin Oncol; 2006 Sep; 24(25):4190-5. PubMed ID: 16943536
[TBL] [Abstract][Full Text] [Related]
19. Duration of testosterone suppression and the risk of death from prostate cancer in men treated using radiation and 6 months of hormone therapy.
D'Amico AV; Renshaw AA; Loffredo B; Chen MH
Cancer; 2007 Oct; 110(8):1723-8. PubMed ID: 17828774
[TBL] [Abstract][Full Text] [Related]
20. Total androgen blockade versus a luteinizing hormone-releasing hormone agonist alone in men with high-risk prostate cancer treated with radiotherapy.
Nanda A; Chen MH; Moran BJ; Braccioforte MH; Dosoretz D; Salenius S; Katin M; Ross R; D'Amico AV
Int J Radiat Oncol Biol Phys; 2010 Apr; 76(5):1439-44. PubMed ID: 19540066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
